Cognetivity Neurosciences announces regulatory approval of first CE-marked medical device Vancouver, British Columbia, January 7, 2020 – Cognetivity Neurosciences…
Read More
Regulatory approval will establish the company’s first CE-marked product. CE marking allows sale of device for medical environments across Europe. VANCOUVER, Dec….
RAZOR reporters visit a company that has developed an AI detector to pick up early signs of dementia
“London-based firm Cognetivity Neurosciences has developed a simple five-minute iPad-based test that can spot the early signs of dementia. With…
VANCOUVER, Nov. 13, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced the…
VANCOUVER, Oct. 29, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today confirmed that…
Innovate UK awards prestigious CA $1.3 million grant to Cognetivity to develop early dementia detection technology in UK National Health Service Cognetivity…
Tom Sawyer, Chief Operating Officer of Cognetivity told The Sociable that their test could be saving time and money by catching…
Cognetivity Neurosciences announces significant expansion of its UK NHS based clinical trial centers
VANCOUVER, Oct. 10, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) has confirmed positive…
VANCOUVER, Sept. 12, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB:1UB; OTCQB: CGNSF) announced that results from its research…
VANCOUVER, Sept. 10, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB:1UB; OTCQB: CGNSF) today announced that its technology…
